Inhibition by Salbutamol of GHRH-Induced GH Release in Type 1 Diabetes Mellitus
| Autor: | Emanuela Arvat, M. Talliano, Ezio Ghigo, Franco Camanni, V. Martina, C. Miola, Mauro Maccario |
|---|---|
| Rok vydání: | 1992 |
| Předmět: |
Adult
Blood Glucose Male endocrine system medicine.medical_specialty endocrine system diseases Endocrinology Diabetes and Metabolism Clinical Biochemistry Adrenergic Stimulation Growth Hormone-Releasing Hormone Biochemistry Glucagon Endocrinology Internal medicine Diabetes mellitus Receptors Adrenergic beta medicine Humans Albuterol business.industry Biochemistry (medical) General Medicine medicine.disease Growth hormone–releasing hormone Growth hormone secretion Diabetes Mellitus Type 1 Somatostatin Growth Hormone Salbutamol Female business medicine.drug |
| Zdroj: | Scopus-Elsevier |
| ISSN: | 1439-4286 0018-5043 |
| DOI: | 10.1055/s-2007-1003379 |
| Popis: | Patients with type 1 diabetes mellitus (IDDM) show augmented GH secretion, which is implicated in the pathogenesis of microvascular complications. On the other hand, it is well known that beta-adrenergic receptors have inhibitory influence on GH secretion, likely via stimulation of hypothalamic somatostatin. Since the possibility of pharmacological suppression of GH secretion would be of value in IDDM, we investigated the effect of salbutamol (SAL, 4 mg orally at -60 min) on the GH response to GHRH (1 micrograms/kg iv at 0 min) in 6 well-controlled (mean HbA1c +/- SEM: 7.3 +/- 0.5%) patients with IDDM. Salbutamol was able to inhibit basal GH levels (p < 0.05) as well as to abolish the GHRH-induced GH rise. After SAL administration, a significant (p < 0.05) reduction of glucagon levels was also found. Our data show that the enhancement of beta 2 adrenergic activity by oral therapeutical doses of SAL inhibits basal and GHRH-stimulated GH secretion in patients with IDDM. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|